Uploaded August 2025 | Updated September 2026, 3 weeks ago
As psychedelic therapies near regulatory approval in Europe, a pressing question arises: How will patients access these treatments through the NHS in the UK? This presentation examines the journey from NICE evaluation to NHS adoption, addressing unique challenges such as therapy-drug combination costs, infrastructure demands, and therapist training. Drawing on case studies and stakeholder insights, we explore practical solutions to ensure equitable access. A vital discussion for clinicians, researchers, and advocates working to integrate these transformative therapies into the UK healthcare system.
Bio:
Martin Gisby has over 15 years of experience in healthcare, specialising in market access, drug commercialisation, and launch strategies. As an independent consultant through Magnetar Access, Martin advises clinical-stage companies on pathways to commercialisation, with a focus on neuroscience, oncology, rare diseases, and psychedelics. He co-authored a forthcoming report on psychedelics and reimbursement in Europe, blending his pharma expertise with a passion for expanding patient access.
As psychedelic therapies near regulatory approval in Europe, a pressing question arises: How will patients access these treatments through the NHS in the UK? This presentation examines the journey from NICE evaluation to NHS adoption, addressing unique challenges such as therapy-drug combination costs, infrastructure demands, and therapist training. Drawing on case studies and stakeholder insights, we explore practical solutions to ensure equitable access. A vital discussion for clinicians, researchers, and advocates working to integrate these transformative therapies into the UK healthcare system.
Bio:
Martin Gisby has over 15 years of experience in healthcare, specialising in market access, drug commercialisation, and launch strategies. As an independent consultant through Magnetar Access, Martin advises clinical-stage companies on pathways to commercialisation, with a focus on neuroscience, oncology, rare diseases, and psychedelics. He co-authored a forthcoming report on psychedelics and reimbursement in Europe, blending his pharma expertise with a passion for expanding patient access.
